| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | AZD8055 | GDSC1000 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.099 | 0.4 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | AZD6244 | FIMM | pan-cancer | AAC | 0.15 | 0.4 |